Wuxi, China
WuXi Biologics began building a $150 million mammalian cell culture manufacturing facility in April of 2015 in Wuxi, China. Designed to utilize disposable bioreactors, the biopharmaceutical production plant will be the largest of its kind in the world and will be able to run continuous or semi-continuous manufacturing processes in addition to traditional modes. Completion is expected by January of 2017. WuXi Biologics is a wholly owned subsidiary of WuXi PharmaTech.
Source
